Palynziq (Pegvaliase)

Pegvaliase, the active ingredient in Palynziq, is an enzyme substitution therapy presented as a solution for subcutaneous injection use. It is indicated for adults with hereditary phenylalanine hydroxylase (PAH) deficiency, commonly known as phenylketonuria (PKU).

GNH USA supplies Palynziq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Palynziq is a pegylated enzyme therapy that targets the metabolic pathway of phenylalanine processing in patients with PKU. - Phenylketonuria (PKU): Reduces blood phenylalanine concentrations, enabling a less restrictive dietary management. - Adult PKU patients with uncontrolled uncontrolled   un  un  un  un  un un un un un un un un un un un un un un un un un un un un un un un. - Adjunctive therapy: Supports dietary treatment when conventional management does not achieve target phenylalanine levels.

Common     ...

Precautions: -  ...

Major